Palvella Therapeutics, Inc.

Palvella Therapeutics is a drug development company working on treatments for rare genetic skin diseases. Their main product candidate is a topical gel called QTORIN rapamycin, which is currently being tested in clinical trials for conditions like microcystic lymphatic malformations and venous malformations of the skin. They are also developing versions of this gel to treat other rare skin conditions where a protein pathway called mTOR is involved. The company has not yet received approval to sell any of these treatments.